Stop COVID Deaths Webinar #98 “NIRMATRELVIR-RITONAVIR, MOLNUPIRAVIR, AT REMDESIVIR: May mabisang gamot na ba laban sa COVID-19?”

View Calendar


The University of the Philippines in partnership with
UP Manila NIH National Telehealth Center and in cooperation with
UP Philippine General Hospital
would like to invite you to join the Fight Against COVID-19!

 

Registration slots are limited to this SPECIAL EDITION of
the STOP C.O.V.I.D. DEATHS Webinar Series.
(Current COVID-19 problems; Other outbreaks; Viruses; Infections; Disasters)
So sign up NOW:
bit.ly/StopCOVIDDeathsWebinar98

 
Webinar #98
"NIRMATRELVIR-RITONAVIR, MOLNUPIRAVIR, AT REMDESIVIR:
May mabisang gamot na ba laban sa COVID-19?”
May 6, 2022 (Friday) 12nn


Presenter:
Dr. Franco Felizarta

Infectious Disease & Internal Medicine Specialist
UP Medical Alumni Association in America (UPMASA)

Reactor:
Dr. Ralph Elvi Villalobos

Consultant, Division of Pulmonary Medicine
UP Philippine General Hospital

Synthesis and Closing Remarks::
Dr. Carmencita D. Padilla

Chancellor
University of the Philippines Manila

-----------------------------------------------------------

Webinar #98
May 6, 2022
"NIRMATRELVIR-RITONAVIR, MOLNUPIRAVIR, AT REMDESIVIR:
May mabisang gamot na ba laban sa COVID-19?”


After two years of the COVID-19 pandemic, there have been great strides in our scientific understanding of the SARSCov2 virus and its variants -- paving the way for vaccination as a foundation for prevention, and home-based antiviral drugs for early treatment, to decrease the risks for hospitalization from severe COVID and preventable deaths.

From the early days of fake news around the use of certain drugs to prevent COVID-19, the scientific community can now comfortably say there are specific treatments for COVID-19 that can be used at home and in hospitals.

Recently, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the "best therapeutic choice for high-risk patients to date".

However, not all countries are able to avail of the drugs. In the Philippines, these treatments are already available, but there is limited public discussion on this.

This WHO recommendation is based on new data from two randomized controlled trials involving 3,078 patients. The data show that the risk of hospitalization is reduced by 85% following this treatment. In a high-risk group (over 10% risk of hospitalization), that means 84 fewer hospitalizations per 1,000 patients.

In this episode of Stop C.O.V.I.D. Deaths, two leading experts in COVID-19 management will discuss the current medicines available for home use as well as hospitalized patients. Dr. Franco Felizarta, a US-based Infectious Disease & Internal Medicine Specialist and a member of the UP Medical Alumni Association in America (UPMASA) will discuss nirmatrelvir with ritonavir, (Paxlovid) as a drug of choice for home-based care; while Dr. Ralph Elvi Villalobos, a Consultant with the Division of Pulmonary Medicine from the Philippine General Hospital will discuss the standard of care for hospitalized patients. Synthesis and Closing Remarks will be delivered by the Chancellor of the University of the Philippines Manila, Dr. Carmencita D. Padilla.

Join us as we learn about the latest anti-virals and how treatment plays a critical role in controlling the pandemic. See you then!

Stay Safe. Stay Healthy. Stay Connected.

Together we can Stop C.O.V.I.D. Deaths!